about
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study.Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximabImmunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 casesAnalysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 StudyCDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority PopulationsIGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomesAddition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flareDevelopmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemiaTumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index
P50
Q35626311-9D40592A-E450-406D-AFAF-D278BC7D0738Q36675182-22676702-CA7B-41E8-92BD-52EE2577F147Q37472823-9D3DA94B-853A-41FE-98DA-EDAD7CA7853FQ38682057-4E6BC546-64BA-443C-86F8-9142C4B35E88Q40834193-79E24387-BE50-4578-B282-EFD7E710FA74Q42711562-B91561E0-6696-4DC2-B787-C32DC486D9D9Q48304637-A6DC7CCE-3355-48EB-966B-00F681E32FFEQ48307279-BB3F8D2C-8D1B-4D60-9E14-4466028458E9Q48370192-0D27F2DE-ACEF-442D-A322-EE7D491427DDQ88195212-E53961AA-E9E9-4150-B0DC-10252DC3564BQ89469980-9D05E854-ED58-479B-B1A6-09DFEA101068Q90250038-21E44F1E-20EC-400A-9561-440A81C12D0BQ90426524-2D58EEC6-3E30-4124-A672-8DCAEDF78200Q90690187-ED58065A-D8AC-41B0-BD43-E386B9643C53Q91590665-80623EA0-E080-4943-9234-01B17753953EQ91774648-233C9361-785B-4E72-A535-8D6C8614FCD0Q91833083-ED683C0C-EC81-48E0-9D45-3B7C350F383E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kari G Chaffee
@ast
Kari G Chaffee
@en
Kari G Chaffee
@es
Kari G Chaffee
@nl
type
label
Kari G Chaffee
@ast
Kari G Chaffee
@en
Kari G Chaffee
@es
Kari G Chaffee
@nl
altLabel
Chaffee KG
@en
prefLabel
Kari G Chaffee
@ast
Kari G Chaffee
@en
Kari G Chaffee
@es
Kari G Chaffee
@nl
P106
P108
P31
P496
0000-0002-7313-1875